We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
StepStone Group
STEP
$4.11B
| $57.5M | 0.08% |
1,391,217
+67,974
| +5% | +$3.36M |
|
252
Intuit
INTU
$85.9B
| $56.5M | 0.08% |
216,500
-22,800
| -10% | -$7.94M |
|
253
Shattuck Labs
STTK
$635M
| $56.4M | 0.08% |
8,122,179
+3,477,222
| +75% | +$21.7M |
|
254
Cardinal Health
CAH
$55.8B
| $56M | 0.08% |
235,892
+13,092
| +6% | +$2.72M |
|
255
Lumentum
LITE
$88.7B
| $56M | 0.08% |
65,300
+62,597
| +2,316% | +$55.8M |
|
256
Air Products & Chemicals
APD
$65.7B
| $55.8M | 0.08% |
190,440
+6,000
| +3% | +$1.75M |
|
257
Penumbra
PEN
$12.6B
| $55.8M | 0.08% |
176,720
+41,720
| +31% | +$13.5M |
|
258
Guardant Health
GH
$21.8B
| $55.8M | 0.08% |
371,763
-444,332
| -54% | -$48.3M |
|
259
Enliven Therapeutics
ELVN
$4.21B
| $55M | 0.08% |
+1,083,313
| New | +$46M |
|
|
NPB
260
Northpointe Bancshares
NPB
$589M
| $54.5M | 0.08% |
2,840,757
+239,254
| +9% | +$4.27M |
|
261
Waters Corp
WAT
$39.8B
| $54.2M | 0.08% |
144,556
+56,700
| +65% | +$19.3M |
|
262
Vistra
VST
$50.7B
| $53.5M | 0.08% |
337,500
-211,800
| -39% | -$32.9M |
|
263
Keysight
KEYS
$56.4B
| $53.5M | 0.08% |
152,835
+14,200
| +10% | +$4.84M |
|
264
Armstrong World Industries
AWI
$7.07B
| $53.4M | 0.07% |
333,000
-242,000
| -42% | -$39.6M |
|
|
HAWK
265
HawkEye 360 Inc
HAWK
$1.61B
| $53M | 0.07% |
+2,622,991
| New | +$72.5M |
|
266
Perella Weinberg Partners
PWP
$1.24B
| $52.9M | 0.07% |
3,311,618
+699,760
| +27% | +$12.8M |
|
267
Ultragenyx Pharmaceutical
RARE
$1.41B
| $52.8M | 0.07% |
1,580,000
+1,100,000
| +229% | +$27.3M |
|
268
Seadrill
SDRL
$3B
| $52.3M | 0.07% |
1,383,436
-1,080,000
| -44% | -$50.3M |
|
269
Regeneron Pharmaceuticals
REGN
$83.2B
| $52.2M | 0.07% |
83,649
-19,448
| -19% | -$13.2M |
|
270
Metropolitan Bank Holding Corp
MCB
$1.12B
| $51.9M | 0.07% |
525,415
-59,218
| -10% | -$5.37M |
|
|
ETOR
271
eToro Group
ETOR
$2.43B
| $51.9M | 0.07% |
1,314,655
+57,936
| +5% | +$2.18M |
|
272
Blackstone
BX
$96.9B
| $51.8M | 0.07% |
440,100
-170,700
| -28% | -$20.5M |
|
273
Targa Resources
TRGP
$62.5B
| $51.3M | 0.07% |
191,300
-1,000
| -0.5% | -$257K |
|
274
Vaxcyte
PCVX
$8.86B
| $51.2M | 0.07% |
880,000
+530,000
| +151% | +$28.8M |
|
275
CME Group
CME
$98.8B
| $51M | 0.07% |
230,931
-15,080
| -6% | -$4.17M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.